IDEAYA reports Q3 net income $1.6M; cash $393.9M; darovasertib registrational trial planned Q1 2023

IDEAYA Biosciences, Inc.

2022-Q3 EPS reported -$0.88 revenue$46,909,000

Cash equivalents and marketable securities of $393.9M as of Sep 30, 2022, sufficient into 2026.
Q3 net income of $1.6M vs. Q2 net loss of $22.1M; collaboration revenue $29.7M (up from $5.9M).
Targeting initiation of potential registrational trial for darovasertib + crizotinib in MUM in Q1 2023.
Initiated IDE397 Phase 2 monotherapy expansion and combination dose escalation with pemetrexed/taxanes.
Targeting IND for PARG inhibitor IDE161 in Q4 2022 and Pol Theta Helicase FIH study in H1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

IDEAYA Biosciences, Inc. reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 8, 2022, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

IDEAYA Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-022837

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.